Davidson Kempner Capital Management LP Graphite Bio, Inc. Transaction History

Davidson Kempner Capital Management LP

  • $2.97 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
BUY
$18.5 - $30.73 $462,500 - $768,250
25,000 New
25,000 $768,000

Others Institutions Holding GRPH

# of Institutions
3
Shares Held
637K
Call Options Held
0
Put Options Held
0
View Full List

About Graphite Bio, Inc.

GRPH Quotes by TradingView
  • Ticker GRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,211,200
  • Description
  • Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...
More about GRPH
Track This Portfolio

Track Davidson Kempner Capital Management LP Portfolio

Follow Davidson Kempner Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Davidson Kempner Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Davidson Kempner Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email